Presenter's Information

Alan C. Yeung, MD

Country USA
Specialty Interventional Cardiologist
  1. Aortic Dissection During TAVR
  2. The UPSTREAM Management of Aortic Stenosis
  3. New Device Platform to Prevent Structural Heart Intervention Complications
  4. Hostile Anatomy - LVOT Calcification
  5. How Recent Guidelines will Change the Practical Indication of TAVR in the Coming Years?
  6. [Featured Lecture 1] The UPSTREAM Management of Aortic Stenosis
  7. Balloon Expandable Valves. New Understandings about Sizing, Positioning, and Repeating
  8. Overview of Cardiac Arrest During Structural Heart Intervention
  9. Optimal Valve Choice in Various TAVR: A Complex Equation to Select One
  10. Antithrombotic Strategy in PCI and AF Patients: Updated Strategy
  11. Many Many Stents: What Should I Select?
  12. Cerebral Protection During TAVR: Why and How?
  13. Expanding Indication of TAVR: Ongoing Trials and Expectations
  14. Sapien 3 THV with Future Coronary Access
  15. Case 1: Complex LM/Multivessel Disease - Hybrid Revascularization
  16. PCI, CABG, or Both: Current Status of Hybrid Coronary Revascularization
  17. Expert Case Review: PCI for Severely Calcified In-Stent Restenosis
  18. TAVR in Low Risk Patients
  19. Sapien 3 or Evolut R: Different Indications?
  20. MV and TV Intervention: Preparing for the Next Revolution
  21. TAVR: Advancing Your Skills: Beyond the Basics
  22. How to Manage Complication TAVR Case
  23. Updates on Antiplatelet Therapy in Cardiovascular Disease
  24. Contemporary DES Thrombosis and Restenosis: Incidence, Mechanisms, and Treatment
  25. Evolving TAVR Indications (Heart Failure, Asymptomatic AS, and AR)
  26. Contemporary and Future Metallic DES: What Do We Expect More from Ongoing PCI Trials?
  27. MV and TV Repair - Current Status and Innovative Future
  28. TVT Registry
  29. TAVR Clinical Trials
  30. PVL: How to Prevent and How to Treat?
  31. Sizing Strategy and PVL Management: Most Experienced Strategy
  32. TAVR for Low Risk Patients: Interventionist\'s Viewpoint
  33. The Evolution of Mitral and Tricuspid Valve Interventions: What It Is? and Where It Needs to Go?
  34. Experience, Current Status and Future of BRS in U.S. Real-World
  35. Technical Lessons for TAVR; Expert Experience
  36. Award Tribute
  37. Comparative Outcomes of Contemporary DES; Are There Major Difference?
  38. Low Coronary Ostium with Narrow or Wide Sinus
  39. Early Discharge Check List to Be Minimalist
  40. Frailty Assessment and How to Define Futile TAVR
  41. Next Issue: How to Manage Failed Transcatheter Heart Valve
  42. Complete Revascularization- The Future Mode of Revascularization in STEMI?
  43. Balloon Expandable System
  44. New Transcatheter Heart Valves
  45. Edward Sapien: Transfemoral
  46. TAVI: Future Perspectives
  47. Edward Sapien
  48. Coronary Obstruction: Treatment and Prevention
  49. Myocardial Bridge: Incidental Finding or Clinical Pathology?
  50. Invited Case Presentation & Focus Review: Multi-vessel Intervention
  51. Mediate a Dispute: Summary
  52. Promus-Element Stent
  53. In-Stent Restenosis - Stop ISR: How to Treat DES-ISR?: Summary
  54. The Updated Evidence-based Guidelines for the Use of Antiplatelet Therapies in ACS
  55. Clinical Decision Making in Patients with Left Main Disease
  56. Use of OCT in Treating a LAD/Diagonal Bifurcation Lesion
  57. Is It Real? Cytochrome P450 Genetic Polymorphisms, Varying Response to Clopidogrel, and Link to Clinical Outcomes : Global Perspective
  58. How to Teach and Train Innovation: US Approach
  59. Experiences of 2nd Generation OCT in Assessment of Complex Coronary Lesions; Can It Give Us Additive Useful Information?
  60. Association between CYP2C19 Genotype and Adverse Clinical Outcomes among PCI Patients: A Meta-analysis
  61. Optimizing the Role of New Anti-thrombotic Regimens in ACS - When, What and Why?
  62. Endothelial Dysfunction Associated with DES: How Important?
  63. New Technologies for Bifurcation: Main Vessel Centric vs Side-Branch Centric
  64. New Devices in Bifurcation Lesions: Do We Really Need One?
  65. Bifurcation Stenting: Implications of the Norfic Study
  66. What Makes Endeavor Different
  67. D2B: An Alliance for Quality
  68. TAXUS Real-World Experience from ARRIVE Registry
  69. Is There a Safety Advantage in the PC Based DES Systems? Possible Mechanisms
  70. Systemic Therapy: Pharmacologic Approach or Cell/Gene Therapy
  71. Technical Aspects and an Update on the EU and US ZOMAXX Clinical Trials
  72. What Are the Proper End Points for DES Trials?
  73. IVUS in Complex PCI
  74. Regional Photodynamic Therapy for Vulnerable Plaque Stabilization I: Antrin
  75. ABT 578 Drug-Eluting Stents II: Preclinical Observations and the Clinical Trial Strategy for the Abbott ZoMax Stent
  76. What Are The Proper End Points for DES Trial
  77. Adjunctive Platelet Glycoprotein IIb/IIIa Receptor Inhibition with Tirofiban before Primary Angioplasty Improves Angiographic Outcomes: Results of the TIrofiban Given in the Emergency Room before Primary Angioplasty(TIGER-PA) Pilot Trial
  78. Percutaneous Bypass: Rebirth as Treatment for CTO
  79. Bifurcation Stenoses: Is There a Solution in Sight ?
  80. Brachytherapy vs DES: Is the Answer in yet ?
Conference Slides
Category